Paxlovid medication lowers risk of COVID-19 death, hospitalization: study – CTV

Feb. 13, 2023

A new study has found that Paxlovid is proven to lower the risk of COVID-19-related death and hospitalization among those likely to experience severe illness.

Paxlovid, which is the brand name for the drug nirmatrelvir–ritonavir, is an antiviral medication used to treat mild to moderate cases of COVID-19.

The study was performed by Ontario researchers and published in the Canadian Medical Association Journal. Scientists concluded that Paxlovid helped prevent COVID-19-related fatalities during the rise of the Omicron variant, between April 4 and Aug. 31, 2022. Data from 8,876 patients treated with nirmatrelvir–ritonavir was compared with the records of 168,669 patients who were not treated with the medication. Most patients included in the research were older than 70 years of age and vaccinated.

Read more:

NationTalk Partners & Sponsors Learn More